Orthocell has today announced some important changes to its Board of Directors.<\/p>\n
The Hon Kim Beazley AC has stepped down from his role as an Independent Non-Executive Director due to health reasons. He will continue to be available in an advisory capacity for US and Defence-related matters.<\/p>\n
Mr Michael McNulty will join the Board as a Non-Executive Director and Chair of the Audit Committee, effective from 1 September 2025. Mr McNulty was the Managing Partner of Deloitte\u2019s Perth office for over 10 years and brings significant leadership experience in Board advisory and strategic consulting to the Orthocell Board.<\/p>\n
Finally, current US-based Orthocell Independent Director, Dr Ravi Thadhani has been elevated to Lead Independent Director. Dr Thadhani will also lead a newly established committee focused on the US commercialisation of Orthocell\u2019s flagship nerve repair product, Remplir\u2122.<\/p>\n
Orthocell Chairman, John Van Der Wielen, said:<\/p>\n
\u201cI would like to extend our sincere gratitude to Kim Beazley for his contributions to the Board. Kim\u2019s extensive US experience, garnered from his extraordinary political and diplomatic career and decades of public service, have been pivotal in strengthening Orthocell\u2019s international expansion, particularly in the US, the largest healthcare market in the world.<\/em><\/p>\n \u201cWe are delighted to welcome Michael McNulty to the Board and as Chair of the Audit Committee. His significant leadership experience as a Director and senior executive across a spectrum of industries, most notably in healthcare and resources, will greatly complement our Board.\u00a0 Meanwhile, Dr Ravi Thadhani\u2019s elevation to Lead Independent Director will bring further collaboration, dedicated to the US market. We look forward to working with Michael and Ravi as we accelerate our global expansion strategy.\u201d<\/em><\/p>\n